Yokoyama Yukio, Doi Shigehiro, Kawai Toru, Yorioka Noriaki
Department of Advanced Nephrology, Graduate School of Biomedical Sciences, Hiroshima University.
Nihon Rinsho. 2010 Feb;68(2):317-22.
Peroxisome proliferator-activated receptor gamma (PPARgamma) is a ligand-dependent transcription factor that has a central role in the regulation of insulin sensitivity and adipocyte differentiation. Expression of PPARgamma has been reported in the kidney, including medullary collecting ducts, glomeruli and tubular cells. Thiazolidinediones (TZDs) are synthetic PPARgamma agonists and are used widely in patients with type 2 diabetes. It has been gradually discovered that TZDs have various other actions, such as vascular protective, anti-inflammatory, anti-fibrotic and anti-proliferative actions, over and above their effects on glucose and lipid metabolism. In this review, we will focus on current knowledge and insights on the role of PPARgamma agonists in kidney diseases, especially in diabetic nephropathy, non-diabetic kidney diseases and dialysis therapy.
过氧化物酶体增殖物激活受体γ（PPARγ）是一种依赖配体的转录因子，在胰岛素敏感性调节和脂肪细胞分化中起核心作用。PPARγ已在肾脏中被报道有表达，包括髓质集合管、肾小球和肾小管细胞。噻唑烷二酮类药物（TZDs）是合成的PPARγ激动剂，广泛用于2型糖尿病患者。人们逐渐发现，TZDs除了对糖脂代谢有影响外，还有各种其他作用，如血管保护、抗炎、抗纤维化和抗增殖作用。在这篇综述中，我们将聚焦于目前关于PPARγ激动剂在肾脏疾病，特别是糖尿病肾病、非糖尿病肾脏疾病和透析治疗中作用的知识和见解。
